Nelfinavir (Viracept) approved: fourth protease inhibitor available. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply. NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Nelfinavir (Viracept) approved: fourth protease inhibitor available. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

AIDS Treat News. 1997 Mar 21;(No 267):1-2. Unique Identifier : AIDSLINE AIDS/97702537
James JS

Abstract: The Food and Drug Administration (FDA) approved nelfinavir (Viracept) for both adult and pediatric use for treatment of HIV infection when antiretroviral therapy is warranted. The drug is the fourth protease inhibitor to gain FDA approval. The recommended dose for adults is 750 mg three times daily, taken with food. The package insert warns of several potential drug interactions, and cautions that the most usual side effect is diarrhea. Developer Agouron Pharmaceuticals has established patient assistance programs to help patients pay for the medication, and are making the drug available through government discount programs.
Keywords: Adolescence Adult Child Child, Preschool *Drug Approval *Drug Costs Drug Therapy, Combination HIV Infections/*DRUG THERAPY HIV Protease Inhibitors/*ADMINISTRATION & DOSAGE/THERAPEUTIC USE Health Services Accessibility Human Isoquinolines/*ADMINISTRATION & DOSAGE/THERAPEUTIC USE Sulfonic Acids/*ADMINISTRATION & DOSAGE/THERAPEUTIC USE United States United States Food and Drug Administration NEWSLETTER ARTICLEKWDadolescenceadultchildchild,preschoolKWDdrugapprovalKWDdrugcostsdrugtherapy,combinationhivinfections/KWDdrugtherapyhivproteaseinhibitors/KWDadministration&dosage/therapeuticusehealthservicesaccessibilityhumanisoquinolines/KWDadministration&dosage/therapeuticusesulfonicacids/KWDadministration&dosage/therapeuticuseunitedstatesunitedstatesfoodanddrugadministrationnewsletterarticle
970830
M9781214

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .